M&A activity in the North American Pharma & Life Sciences industry started strong this year with 101 announced deals in the first quarter, a 20% increase over Q4 2010 and almost double Q1 2010’s total of 53 transactions.
While the number of deals increased respectably, disclosed deal value remained stable at $19.1 billion. This relatively flat trend is attributed to continued growth in the number of carve-out transactions, which represented 38% of deals this quarter, up from Q4’s 31%.
There were 4 deals valued at over $1 billion in Q1, distributed among the three sub-sectors: Medical Devices, Life Sciences Tools & Services and Drug Development. Two transactions fell just shy of the $1 billion value, both in Drug Development.